Winton Group’s CRISPR Therapeutics CRSP Stock Holding History

Winton Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,468	Closed	-$343K	–	963
2022 Q1	$343K	Sell	5,468 -1,912	-26%	-$120K	0.02%	785
2021 Q4	$559K	Sell	7,380 -874	-11%	-$76.4K	0.03%	647
2021 Q3	$924K	Buy	+8,254	New	+$1.04M	0.05%	546
2021 Q1	–	Sell	-5,770	Closed	-$883K	–	1384
2020 Q4	$883K	Sell	5,770 -15,702	-73%	-$1.86M	0.06%	474
2020 Q3	$1.8M	Sell	21,472 -31,190	-59%	-$2.77M	0.06%	577
2020 Q2	$3.87M	Sell	52,662 -30,330	-37%	-$1.77M	0.1%	328
2020 Q1	$3.52M	Buy	82,992 +30,477	+58%	+$1.57M	0.09%	384
2019 Q4	$3.2M	Buy	+52,515	New	+$2.87M	0.04%	620

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Winton Group's CRSP Position: Q2 2022 in Review

Winton Group sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 5,468 shares — an estimated $343K sold.

Winton Group first reported a position in CRSP in Q4 2019 and held it in 8 quarters. The position peaked at $3.87M in Q2 2020. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

Winton Group reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
Winton Group sold 5,468 CRISPR Therapeutics shares in Q2 2022, an estimated $343K.
Winton Group first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 8 quarters.
Winton Group's CRISPR Therapeutics position peaked at $3.87M in Q2 2020.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Winton Group's 13F filing for Q2 2022, filed 10 Aug 2022.